Skip to main content

Breast cancer

News and opinion

13-12-2018 | HER2-positive breast cancer | News

Adjuvant trastuzumab emtansine reduces HER2-positive breast cancer recurrence risk

Among patients with early-stage HER2-positive breast cancer who have residual disease after neoadjuvant therapy and surgery, the use of trastuzumab emtansine instead of trastuzumab leads to significant improvements in invasive disease-free survival, indicate KATHERINE trial findings.


N Engl J Med 2018; doi:10.1056/NEJMoa1814017
SABCS 2018; San Antonio, Texas, USA; 4–8 December

03-12-2018 | FDA | Drug approval | News


Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

06-11-2018 | Breast cancer | News

NCRI 2018

Early risers may have reduced breast cancer risk

Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.


NCRI 2018; Glasgow, UK; 4–6 November

06-11-2018 | Chemoprevention | News

NCRI 2018

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.


NCRI 2018; Glasgow, UK

05-11-2018 | Breast cancer | ESMO 2018 | News

Epigenetic therapy shows promise for HR-positive advanced breast cancer

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.


ESMO 2018; Munich, Germany; 19–23 October

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

24-10-2018 | Tamoxifen | ESMO 2018 | Video

Serum analysis sheds light on tamoxifen adherence

Barbara Pistilli discusses the CANTO COMPLETE study of premenopausal breast cancer patient adherence to endocrine therapy (4:31).

24-10-2018 | Breast cancer | ESMO 2018 | Video

Evaluating alpelisib addition to standard of care in SOLAR-1

We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

23-10-2018 | Breast cancer | ESMO 2018 | News

News in brief

Serum testing reveals tamoxifen therapy nonadherence

Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.

21-10-2018 | Triple-negative breast cancer | ESMO 2018 | News

IMpassion130 supports atezolizumab use in triple-negative breast cancer

Results for the IMpassion130 trial support the combination of atezolizumab and nab-paclitaxel for the treatment of metastatic triple-negative breast cancer, especially among patients with programmed cell death ligand 1-positive disease.


N Engl J Med 2018; doi:10.1056/NEJMoa1809615
ESMO 2018; Munich, Germany: 18–23 October

21-10-2018 | Breast cancer | ESMO 2018 | News

Adding alpelisib to fulvestrant boosts PI3KCA-mutant metastatic breast cancer PFS

Patients with hormone receptor-positive, HER2-negative metastatic breast cancer harboring PI3KCA mutations derive a significant progression-free survival benefit when fulvestrant is supplemented with the PI3K inhibitor alpelisib, phase III data show.


ESMO 2018; Munich, Germany; 19–23 October

20-10-2018 | Breast cancer | ESMO 2018 | News

Further evidence for palbociclib addition in advanced breast cancer

PALOMA-3 trial findings show that overall survival is significantly improved with the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer and sensitivity to prior endocrine therapy.


ESMO 2018; Munich, Germany; 19–23 October
N Engl J Med 2018; doi:10.1056/NEJMoa1810527

12-10-2018 | Breast cancer | News

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.


BMJ 2018; 363: k3845

11-10-2018 | Breast cancer | News

News in brief

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

10-10-2018 | Chemotherapy | News

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.


Cancer 2018; doi:10.1002/cncr.31760
JAMA Network Open 2018; 1: e183023

09-10-2018 | Breast cancer | News

Lurbinectedin activity shown in metastatic breast cancer

Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.


J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6558

18-09-2018 | EMA | News


Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

03-09-2018 | Advanced breast cancer | News

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.


N Engl J Med 2018; 379: 753–763
Ann Oncol 2018; doi:10.1093/annonc/mdy257

31-08-2018 | Breast cancer | News

In other news: Breast cancer treatment effects

The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.

image credits